Eli Lilly and Company LLY
1,354.00 USD -10.73 (-0.79%)
At closeNov 6, 2026, 7:58 PM EST
1,357.00 +3.00 +0.22%
After hours · Nov 6, 7:58 PM ET
1,333.22 Day range 1,377.28
851.21 52-week range 1,417.99
- YTD
- +25.99%
- 1 year
- +44.44%
News
fool.com Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence Some of Eli Lilly's products beyond its core therapeutic area are performing well. It also boasts a deep and diversified pipeline.
benzinga.com Telehealth Giant Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery Eli Lilly partners with Hims & Hers to offer Zepbound and Foundayo directly to telehealth patients with self-pay options starting at $149.
benzinga.com Growth Lead Sectors In Friday Trading As Defensives Trail Seven sectors are higher and four are lower in Friday’s regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap…
benzinga.com Eli Lilly And Hims & Hers Partner To Expand Access To Zepbound And Orforglipron At Standard Self-Pay Prices Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platformEli Lilly and Company (NYSE:LLY) and Hims & Hers Health, Inc. (NYSE:HIMS) today announced…
247wallst.com Prediction: The Weight-Loss Drug Boom Could Be Just the Beginning for Lilly Eli Lilly just crushed earnings and raised guidance, yet the most compelling part of its story has almost nothing to do with what already happened.
benzinga.com LifeMD Announces Agreement For Its Pharmacies To Directly Dispense, Ship Eli Lilly's Self-Pay GLP-1 Medicines LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an arrangement with Eli Lilly and Company (Lilly) that enables LifeMD's affiliated pharmacy to directly…
prnewswire.com Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity Pivotal results from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some…
defenseworld.net Eli Lilly and Company $LLY Stock Holdings Lifted by Caldwell Trust Co Caldwell Trust Co increased its stake in Eli Lilly and Company (NYSE: LLY) by 3.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).…
defenseworld.net Eli Lilly and Company $LLY Stock Bought by Compass Financial Management LLC Compass Financial Management LLC grew its holdings in Eli Lilly and Company (NYSE: LLY) by 19.1% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange…
defenseworld.net Focused Wealth Management Inc Sells 443 Shares of Eli Lilly and Company $LLY Focused Wealth Management Inc trimmed its stake in shares of Eli Lilly and Company (NYSE: LLY) by 13.5% during the third quarter, according to its most recent filing with the Securities and Exchange…
defenseworld.net Eli Lilly and Company $LLY Stock: AIA Group Ltd Lowers Stake AIA Group Ltd trimmed its position in shares of Eli Lilly and Company (NYSE: LLY) by 11.2% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange…
benzinga.com Novo Nordisk Raises 2026 Outlook As Wegovy Pill Shines Novo Nordisk (NVO) stock jumped after Q3 earnings beat estimates, driven by record Wegovy pill demand and a raised 2026 outlook.
seekingalpha.com Eli Lilly: The True Frontier Of Real-World AI Monetization Eli Lilly is positioned as the primary beneficiary of AI-driven drug discovery, leveraging its scale and research infrastructure. LLY's integration of AI accelerates new molecule development,…
prnewswire.com Treasury's Refunding Details Are Up Next as Five Large Companies Report Higher Revenue /PRNewswire/ -- Market Updates News Commentary - U.S. stock index futures were mixed early Wednesday after a split session on Tuesday. As of 2:22 a.m. ET,
seekingalpha.com Eli Lilly: Higher Volume, Lower Realized Prices Eli Lilly and Company delivered 39% revenue growth, driven by 53% volume gains despite a 15% decline in realized prices; gross margin rose to 83.9%. Eli Lilly's Strong Buy rating reflects robust…
zacks.com Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
zacks.com LLY Stock Up Almost 10% After a Robust Q3: Time to Buy, Sell or Hold? Eli Lilly and Company's LLY stock has risen 9.6% since it announced solid third-quarter results on Oct. 29. Lilly's third-quarter earnings and revenues comfortably exceeded estimates.
247wallst.com Eli Lilly Just Delivered Another Monster Quarter. But There's More to This Story Than Weight-Loss Drugs Eli Lilly's weight-loss drugs get all the headlines, but CEO David Ricks is betting the company's next act looks nothing like its last one. Here is what it would actually take for shares to reach…
seekingalpha.com Eli Lilly: Softer Growth Ahead (Rating Downgrade) Eli Lilly delivered robust results last week. But after maintaining a Strong Buy rating on the stock since May, I'm interested in watching out for what can go wrong. Indeed, there are signs of…
247wallst.com Eli Lilly Jumped 6% After Earnings. It's Up 68% in a Year. Mounjaro and Zepbound just handed Lilly a blowout quarter, but falling realized drug prices and one-time revenue boosts that won't repeat raise real questions about whether the rally holds from here.- benzinga.com Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1600 Cantor Fitzgerald analyst Carter Gould maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1440 to $1600.
benzinga.com Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism Elon Musk praises Eli Lilly’s upcoming drug pipeline as CEO Dave Ricks responds to skepticism about innovation at big biotech companies.
benzinga.com JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $1650 JP Morgan analyst Chris Schott maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1500 to $1650.
benzinga.com Scotiabank Maintains Sector Outperform on Eli Lilly, Raises Price Target to $1605 Scotiabank analyst Louise Chen maintains Eli Lilly (NYSE:LLY) with a Sector Outperform and raises the price target from $1300 to $1605.
benzinga.com Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1596 Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1430 to $1596.
benzinga.com Eli Lilly 'Deserves' Stock Upside: Analyst Eli Lilly beats Q3 estimates on Mounjaro and Zepbound growth. Analysts lift price targets as 2026 revenue guidance jumps to $92 billion.
benzinga.com Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $1500 Wells Fargo analyst Mohit Bansal maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1330 to $1500.
benzinga.com RBC Capital Maintains Outperform on Eli Lilly, Raises Price Target to $1600 RBC Capital analyst Trung Huynh maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $1500 to $1600.- benzinga.com Truist Securities Reiterates Buy on Eli Lilly, Raises Price Target to $1612 Truist Securities analyst Srikripa Devarakonda reiterates Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1376 to $1612.
benzinga.com Defensives Lead Sectors In Friday Trading As Growth Trails Five sectors are higher and six are lower in Friday's regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than separated, while Technology sits…- benzinga.com Argus Research Maintains Buy on Eli Lilly, Raises Price Target to $1550 Argus Research analyst Jasper Hellweg maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1300 to $1550.
benzinga.com Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Trade Mixed as AMZN, INTC Slide After Q3 Earnings—DELL, LLY, AZN in Focus (UPDATED) U.S. stock were mixed on Friday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures moved in different direction.
benzinga.com LLY Stock Hits Record as CEO Says Middle-Income Consumers Are Driving Pharma’s ‘Largest New Category Expansion’ Eli Lilly stock hits a record close as CEO David Ricks points to middle-income demand and a historic pharma category expansion.
benzinga.com Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.- benzinga.com Eli Lilly and Company Reports $303M In Q3 2026 Special Charges, Bringing 9-Month Total To $1.3B, Primarily Driven By Intangible Asset Impairment, Acquisition Costs And Litigation Note 5: Asset Impairment, Restructuring, and Other Special ChargesAsset impairment, restructuring, and other special charges recognized during the three and nine months ended September 30, 2026 were…
benzinga.com Eli Lilly Q3 2026 Earnings Call Transcript Eli Lilly (NYSE:LLY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com 8 Of 11 Sectors Rise Thursday As Defensives Lead Eight sectors are higher and three are lower in Thursday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Health…
benzinga.com Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and Crocs, despite the Dow falling 150 points.
benzinga.com Eli Lilly Mounjaro Clocks 65% Jump in Sales to Massive $10.7 billion Eli Lilly tops Q3 forecasts on surging Mounjaro sales, raises 2026 revenue outlook to $92 billion, and hits new 52-week highs despite an EPS forecast trim.
benzinga.com Eli Lilly Lowers FY2026 Adj EPS Guidance from $35.50-$36.50 to $35.00-$36.00 vs $34.04 Est; Raises FY2026 Sales Guidance from $85.000B-$87.000B to $91.000B-$92.000B vs $88.848B Est Eli Lilly (NYSE:LLY) lowers FY2026 Adj EPS guidance from $35.50-$36.50 to $35.00-$36.00 vs $34.04 analyst estimate. Raises FY2026 sales outlook from $85.000 billion-$87.000 billion to $91.000…- benzinga.com Eli Lilly Q3 Adj. EPS $7.48 Beats $6.50 Estimate, Sales $24.397B Beat $22.610B Estimate Eli Lilly (NYSE:LLY) reported quarterly earnings of $7.48 per share which beat the analyst consensus estimate of $6.50 by 15.08 percent. This is a 6.55 percent increase over earnings of $7.02 per…
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will S&P 500 open higher? Polymarket odds dip to 47% as Wall Street weighs a tech selloff, Amazon earnings, PCE inflation, and cooling oil.
benzinga.com Dow Gains For Third Session Following Fed Decision: Investor Sentiment Improves, Greed Index Remains In ‘Fear’ Zone U.S. stocks rose after the Fed held rates steady, but CNN's Fear & Greed Index improved to 36, remaining in the Fear zone.
benzinga.com Amazon, Alphabet and 3 Stocks to Watch Heading Into Thursday Stocks in focus: Amazon and Eli Lilly report earnings; Alphabet missed estimates and fell 10%; Microsoft beat; Caterpillar reports today.
benzinga.com Eli Lilly Shares Trending On Retatrutide Win Ahead Of Earnings: What You Should Know Eli Lilly shares rise 1.89% after hours following positive Phase 3 retatrutide diabetes trial results ahead of quarterly earnings.
benzinga.com Traders Are Pricing a 7% Swing in Amazon Ahead of Earnings Amazon, Intel, Sandisk and six other stocks report earnings Thursday. See implied moves, analyst estimates and the billions in market value at stake.
benzinga.com Amazon, Eli Lilly On Deck Thursday As AWS Growth, Drug Demand Face Test Amazon headlines Thursday’s reports, with investors focused on whether accelerating AWS growth and heavy AI spending can support the next leg of its expansion. Eli Lilly, Mastercard, Merck,…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Cyclicals Lead Sectors In Wednesday Trading As Real Estate Trails Four sectors are higher and seven are lower in Wednesday’s regular session, with cyclical and defensive sectors split at the top of the table. The leaders are separated rather than clustered, with…
benzinga.com Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED) Novo Nordisk fails to block Eli Lilly’s weight-loss drug ads as a judge finds little evidence of market impact or lasting harm.